# A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

> **NCT01002820** · PHASE2 · COMPLETED · sponsor: **Marinus Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Epilepsy, Complex Partial

## Interventions

- **DRUG:** ganaxolone

## Key facts

- **NCT ID:** NCT01002820
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-10
- **Final completion:** 2013-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01002820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01002820, "A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01002820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*